Multipharma Group has launched Inceptua Medicines Access, a new business unit specilising in providing access to pre-approval and unlicensed medicines in an increasingly complex environment. It will be led by a recognised team of specialist industry experts who have been involved in many of the initiatives that have grown and shaped the market and built access solutions for the benefit of patients, while mitigating the risks involved in providing access to pre-approval and unlicensed treatments.

Inceptua Medicines Access includes three distinct but collaborative divisions:

  • Inceptua Medicines Access Pharma focuses on engaging with biopharmaceutical clients to provide controlled pre-approval access programs to their medicines
  • Inceptua Medicines Access Healthcare focuses on sourcing and supplying unlicensed medicines on an on-demand basis for hospitals, pharmacists and physicians
  • Inceptua Medicines Access Consulting offers strategy support services to biopharmaceutical clients

Mark Corbett (centre left) is Executive Vice-President of Inceptua Medicines Access. He has over 20 years’ industry experience in the areas of access to unlicensed medicines, Named Patient, Pre-Approval, Early Access, Expanded Access, Managed Access and Compassionate Use Programmes. Previously, he was Managing Director at Idis, Global Access, Senior Vice President at Clinigen Global Access Programs, Head of European Business Development at Idis and an Independent Pharmaceutical Consultant. Mark has extensive specialist knowledge and operational expertise gained through the implementation of more than 150 global programs for a variety of biopharmaceutical companies across all stages of the drug lifecycle.

Andrew Cummins (far right) is Vice-President of Inceptua Medicines Access Healthcare. He has over 20 years’ international experience in commercial leadership roles in the medicines access, pharmaceutical and medical device industries. Previously, he worked at Idis, Clinigen and Caligor, holding roles of Global Sales and Operations and General Manager of unlicensed medicines business. This involved account management of both wholesale and hospital customers in over 40 markets, and servicing biopharmaceutical companies delivering exclusive distribution on their behalf into unlicensed markets.

Gary Scarle (centre right) is Vice-President Operations of Inceptua Medicines Access. He has spent more than 25 years working in the pharmaceutical industry in a variety of different roles. He has held senior management positions in Training, Sales Operations and Strategic Co-ordination. Most recently, he worked at Servier laboratories as Head of Human Resources. He has also been a Trustee, and was the Chair of the Board of Trustees of the company pension scheme. Gary brings experience and expertise in project management, and in the successful design and implementation of processes and policies.

Dr Stuart Bell (far left) is Head of Inceptua Medicines Access Consulting. He has more than 20 years of healthcare and pharma consulting experience, with a particular focus in unlicensed medicines and pre-approval access. Most recently, Stuart held the role of Principal in Quintiles IMS’ Real-World Insights Division, and before that he was Director of Strategic Services at Clinigen/Idis. He brings expertise in real-world evidence, rare diseases, orphan products and oncology and has a track record of successful strategic consulting and service delivery to support global/regional real-world evidence, market access objectives and product launch.